valproic acid has been researched along with HIV in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells." | 3.73 | Valproic acid does not affect markers of human immunodeficiency virus disease progression. ( Ances, BM; Buzzell, M; Ellis, RJ; Grant, I; Lazaretto, D; Letendre, S; Marcotte, TD; Marquie-Beck, J, 2006) |
| "Among 1345 HIV/AIDS persons in active care between 2001 and 2007, 169 individuals were exposed to AEDs for the following indications: peripheral neuropathy/neuropathic pain (60%), seizure/epilepsy (24%), mood disorder (13%) and movement disorder (2%)." | 1.36 | Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. ( Gill, MJ; Krentz, HB; Lee, K; Maingat, F; Power, C; Siemieniuk, RA; Vivithanaporn, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, K | 1 |
| Vivithanaporn, P | 1 |
| Siemieniuk, RA | 1 |
| Krentz, HB | 1 |
| Maingat, F | 1 |
| Gill, MJ | 1 |
| Power, C | 1 |
| Cohen, J | 1 |
| Ances, BM | 1 |
| Letendre, S | 1 |
| Buzzell, M | 1 |
| Marquie-Beck, J | 1 |
| Lazaretto, D | 1 |
| Marcotte, TD | 1 |
| Grant, I | 1 |
| Ellis, RJ | 1 |
| Maggi, JD | 1 |
| Halman, MH | 1 |
| Dasgupta, A | 1 |
| Wells, A | 1 |
| Chow, L | 1 |
5 other studies available for valproic acid and HIV
| Article | Year |
|---|---|
Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anticonvulsants; Calcium Channel Blockers; CD4 Antigens; | 2010 |
HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Enfuvirtide; Enz | 2005 |
Valproic acid does not affect markers of human immunodeficiency virus disease progression.
Topics: Adult; Anticonvulsants; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Progre | 2006 |
The effect of divalproex sodium on HIV replication in vivo.
Topics: Adult; CD4 Lymphocyte Count; Enzyme Inhibitors; Female; HIV; HIV Infections; Humans; Male; Middle Ag | 2007 |
Effect of heating human sera at a temperature necessary to deactivate human immunodeficiency virus on measurement of free phenytoin, free valproic acid, and free carbamazepine concentrations.
Topics: Anticonvulsants; Blood; Carbamazepine; Hemofiltration; HIV; Hot Temperature; Humans; Phenytoin; Valp | 1999 |